Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Betazole. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Betazole SCHEMBL1237744 | 0.98 | HRH1 (0.39) | — | |
| Betazole SCHEMBL1237742 | 0.98 | — | — | |
| Betazole SCHEMBL2891008 | 0.87 | AOC3 (0.33) | — | |
| SCHEMBL1187446 | 0.86 | — | — | |
| SCHEMBL5815984 | 0.83 | HRH1 (0.47) | — | |
| Betazole SCHEMBL3336046 | 0.82 | USP2 (0.68) | — | |
| Hydrochloric Acid SCHEMBL17361360 | 0.82 | — | — | |
| SCHEMBL11323243 | 0.81 | CYP1A2 (0.47) | — | |
| SCHEMBL4505350 | 0.81 | — | — | |
| SCHEMBL244009 | 0.80 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 913 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260148852-A1 | ORGANIC MOLECULE EXPOSOMICS | LINUS BIOTECHNOLOGY INC. (US) | 2026-05-28 | — | — | US | claimed |
| EP-4704971-A1 | GAMMA STIMULATION AND NEUROMODULATOR COMBINATION THERAPY | Cognito Therapeutics, Inc. (US) | 2026-03-11 | — | — | EP | claimed |
| EP-4673725-A2 | ORGANIC MOLECULE EXPOSOMICS | Linus Biotechnology Inc. (US) | 2026-01-07 | — | — | EP | claimed |
| WO-2025111482-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS | BEXSON BIOMEDICAL, INC. (US) | 2025-05-30 | — | — | WO | claimed |
| US-12295388-B2 | Methods of modulating gastrointestinal metabolites | DSM IP ASSETS B.V. (NL) | 2025-05-13 | — | — | US | claimed |
| CN-119075702-A | Pollution-resistant seawater desalination membrane and preparation method thereof | 湖南澳维科技股份有限公司 | 2024-12-06 | — | — | CN | claimed |
| US-20240398819-A1 | UTILITY OF VITAMIN D, FOLIC ACID AND NADH TO IMPROVE LIGAMENT INJURY PREVENTION CHARACTERISTICS | RHODE ISLAND HOSPITAL | 2024-12-05 | — | — | US | claimed |
| WO-2024229174-A1 | GAMMA STIMULATION AND NEUROMODULATOR COMBINATION THERAPY | Cognito Therapeutics, Inc. (US) | 2024-11-07 | — | — | WO | claimed |
| WO-2024182308-A2 | ORGANIC MOLECULE EXPOSOMICS | LINUS BIOTECHNOLOGY INC. (US) | 2024-09-06 | — | — | WO | claimed |
| US-20220125074-A1 | METHODS OF MODULATING GASTROINTESTINAL METABOLITES | DSM IP ASSETS B.V. (NL) | 2022-04-28 | — | — | US | claimed |
| WO-2001006756-A2 | USE OF DIPHENYLIODONIUM FOR THE ACTIVATION AND PROTECTION OF CYTOTOXIC LYMPHOCYTES | MAXIM PHARMACEUTICALS, INC. (US) | 2001-01-25 | — | — | WO | claimed |
| EP-0652768-B1 | A pharmaceutical preparation for the synergistic activation of natural killer cells | MAXIM PHARM INC (US) | 2000-05-03 | — | — | EP | claimed |
| WO-2000010600-A2 | ACTIVATION AND PROTECTION OF T-CELLS (CD4+ AND CD8+) USING AN H¿2? RECEPTOR AGONIST AND OTHER T-CELL ACTIVATING AGENTS | MAXIM PHARMACEUTICALS, INC. (US) | 2000-03-02 | — | — | WO | claimed |
| US-5922403-A | ADDING ENCAPSULANT TO HIGHLY DISPERSED COLLOIDAL SUSPENSION OF SOLID PARTICLES TO ENCAPSULATE INDIVIDUAL PARTICLES; AGGLOMERATING; ISOLATING ENCAPSULATED PARTICLES BY SEPARATION FROM SOLVENT LAYER | TECLE, BERHAN | 1999-07-13 | — | — | US | claimed |
| EP-0917501-A1 | METHOD FOR ISOLATING ULTRAFINE AND FINE PARTICLES AND RESULTING PARTICLES | Tecle, Berhan (US) | 1999-05-26 | — | — | EP | claimed |
| US-5728378-A | ANTITUMOR AND ANTIVIRUS AGENTS | MAXIM PHARMACEUTICALS, INC. (US) | 1998-03-17 | — | — | US | claimed |
| WO-1997033713-A1 | METHOD FOR ISOLATING ULTRAFINE AND FINE PARTICLES AND RESULTING PARTICLES | TECLE BERHAN (US) | 1997-09-18 | — | — | WO | claimed |
| EP-0652768-A1 | PREPARATION FOR ACTIVATION OF NATURAL KILLER CELLS (NK-CELLS), SAID PREPARATION CONTAINING INTERFERON-ALPHA AND HISTAMINE, SEROTONIN OR SUBSTANCES WITH CORRESPONDING RECEPTOR ACTIVITY | MAXIM PHARMACEUTICALS, INC. (US) | 1995-05-17 | — | — | EP | claimed |
| WO-1993024144-A1 | PREPARATION FOR ACTIVATION OF NATURAL KILLER CELLS (NK-CELLS), SAID PREPARATION CONTAINING INTERFERON-α AND HISTAMINE, SEROTONIN OR SUBSTANCES WITH CORRESPONDING RECEPTOR ACTIVITY | SYNTELLO INC. (US) | 1993-12-09 | — | — | WO | claimed |
| US-4548805-A | Non-invasive test for gastric acid | SACK DAVID A | 1985-10-22 | — | — | US | claimed |